Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

1.

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.

Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, Ghossein RA, Ricarte-Filho JC, Domínguez JM, Shen R, Tuttle RM, Larson SM, Fagin JA.

N Engl J Med. 2013 Feb 14;368(7):623-32. doi: 10.1056/NEJMoa1209288.

PMID:
23406027
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements.

Hayes DN, Lucas AS, Tanvetyanon T, Krzyzanowska MK, Chung CH, Murphy BA, Gilbert J, Mehra R, Moore DT, Sheikh A, Hoskins J, Hayward MC, Zhao N, O'Connor W, Weck KE, Cohen RB, Cohen EE.

Clin Cancer Res. 2012 Apr 1;18(7):2056-65. doi: 10.1158/1078-0432.CCR-11-0563. Epub 2012 Jan 12.

PMID:
22241789
[PubMed - indexed for MEDLINE]
Free Article
3.

Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.

Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA.

J Clin Oncol. 2011 Jun 10;29(17):2357-63. doi: 10.1200/JCO.2010.33.9473. Epub 2011 Apr 25.

PMID:
21519026
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.

Lind P, Kohlfürst S.

Semin Nucl Med. 2006 Jul;36(3):194-205. Review.

PMID:
16762610
[PubMed - indexed for MEDLINE]
5.

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.

Kirkwood JM, Bastholt L, Robert C, Sosman J, Larkin J, Hersey P, Middleton M, Cantarini M, Zazulina V, Kemsley K, Dummer R.

Clin Cancer Res. 2012 Jan 15;18(2):555-67. doi: 10.1158/1078-0432.CCR-11-1491. Epub 2011 Nov 2.

PMID:
22048237
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases.

Sabra MM, Dominguez JM, Grewal RK, Larson SM, Ghossein RA, Tuttle RM, Fagin JA.

J Clin Endocrinol Metab. 2013 May;98(5):E829-36. doi: 10.1210/jc.2012-3933. Epub 2013 Mar 26.

PMID:
23533233
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.

Patel SP, Lazar AJ, Papadopoulos NE, Liu P, Infante JR, Glass MR, Vaughn CS, LoRusso PM, Cohen RB, Davies MA, Kim KB.

Cancer. 2013 Feb 15;119(4):799-805. doi: 10.1002/cncr.27790. Epub 2012 Sep 12.

PMID:
22972589
[PubMed - indexed for MEDLINE]
Free Article
8.

¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy.

Rosenbaum-Krumme SJ, Görges R, Bockisch A, Binse I.

Eur J Nucl Med Mol Imaging. 2012 Sep;39(9):1373-80. doi: 10.1007/s00259-012-2065-4. Epub 2012 Jun 21.

PMID:
22718304
[PubMed - indexed for MEDLINE]
9.

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, Maloney L, Gordon G, Simmons H, Marlow A, Litwiler K, Brown S, Poch G, Kane K, Haney J, Eckhardt SG.

J Clin Oncol. 2008 May 1;26(13):2139-46. doi: 10.1200/JCO.2007.14.4956. Epub 2008 Apr 7.

PMID:
18390968
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.

Holt SV, Logié A, Odedra R, Heier A, Heaton SP, Alferez D, Davies BR, Wilkinson RW, Smith PD.

Br J Cancer. 2012 Feb 28;106(5):858-66. doi: 10.1038/bjc.2012.8. Epub 2012 Feb 16.

PMID:
22343622
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma.

Min JJ, Chung JK, Lee YJ, Jeong JM, Lee DS, Jang JJ, Lee MC, Cho BY.

Eur J Nucl Med. 2001 May;28(5):639-45.

PMID:
11383871
[PubMed - indexed for MEDLINE]
12.

Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy.

de Keizer B, Brans B, Hoekstra A, Zelissen PM, Koppeschaar HP, Lips CJ, van Rijk PP, Dierckx RA, de Klerk JM.

Eur J Nucl Med Mol Imaging. 2003 Mar;30(3):367-73. Epub 2002 Dec 19.

PMID:
12634964
[PubMed - indexed for MEDLINE]
13.

Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.

Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn JA, John R, Nutting CM, Newbold K, Lemon C, Gerrard G, Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A.

N Engl J Med. 2012 May 3;366(18):1674-85. doi: 10.1056/NEJMoa1109589.

PMID:
22551128
[PubMed - indexed for MEDLINE]
Free Article
14.

Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma.

Patel SP, Kim KB.

Expert Opin Investig Drugs. 2012 Apr;21(4):531-9. doi: 10.1517/13543784.2012.665871. Epub 2012 Mar 7. Review.

PMID:
22394161
[PubMed - indexed for MEDLINE]
15.

Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.

Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, Ghossein RA, Fagin JA.

Cancer Res. 2009 Jun 1;69(11):4885-93. doi: 10.1158/0008-5472.CAN-09-0727.

PMID:
19487299
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244).

Boers-Sonderen MJ, Desar IM, Blokx W, Timmer-Bonte JN, van Herpen CM.

Anticancer Drugs. 2012 Aug;23(7):761-4. doi: 10.1097/CAD.0b013e328350737d.

PMID:
22293660
[PubMed - indexed for MEDLINE]
17.

A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer.

Short SC, Suovuori A, Cook G, Vivian G, Harmer C.

Clin Oncol (R Coll Radiol). 2004 Dec;16(8):569-74.

PMID:
15630851
[PubMed - indexed for MEDLINE]
18.

Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine.

Wang W, Larson SM, Tuttle RM, Kalaigian H, Kolbert K, Sonenberg M, Robbins RJ.

Thyroid. 2001 Dec;11(12):1169-75.

PMID:
12186505
[PubMed - indexed for MEDLINE]
19.

Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of TSH stimulation and number of preceding radioiodine therapies.

Hartung-Knemeyer V, Nagarajah J, Jentzen W, Ruhlmann M, Freudenberg LS, Stahl AR, Bockisch A, Rosenbaum-Krumme SJ.

Ann Nucl Med. 2012 Nov;26(9):723-9. doi: 10.1007/s12149-012-0632-1. Epub 2012 Jul 17.

PMID:
22802008
[PubMed - indexed for MEDLINE]
20.

First experience with proteasome inhibitor treatment of radioiodine nonavid thyroid cancer using bortezomib.

Putzer D, Gabriel M, Kroiss A, Madleitner R, Eisterer W, Kendler D, Uprimny C, Bale RJ, Gastl G, Virgolini IJ.

Clin Nucl Med. 2012 Jun;37(6):539-44. doi: 10.1097/RLU.0b013e31824c5f24.

PMID:
22614183
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk